Letter to the EditorLife-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
References (9)
- et al.
An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder
Blood
(2004) - et al.
Epithelial IL-18 equilibrium controls barrier function in colitis
Cell
(2015) - et al.
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response
Immunity
(1999) - et al.
Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling
Annu Rev Immunol
(2015)
Cited by (251)
Interleukin-18 in chronic pain: Focus on pathogenic mechanisms and potential therapeutic targets
2024, Pharmacological ResearchMolecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis
2023, Rheumatic Disease Clinics of North AmericaNLRC4 gain-of-function variant is identified in a patient with systemic lupus erythematosus
2023, Clinical ImmunologyDistinct roles of IL-18 and IL-1β in murine model of macrophage activation syndrome
2023, Journal of Allergy and Clinical ImmunologyCold Urticaria Syndromes: Diagnosis and Management
2023, Journal of Allergy and Clinical Immunology: In Practice
S.W.C., L.M., A.de.J., and R.G.-M. were supported by the Intramural Research Program of the National Institute of Arthritis, Musculoskeletal, and Skin Diseases. E.M.B. was supported by the National Institutes of Health (grant no. R01 HL112836-A1), the Nancy Taylor Foundation, and Sean Fischel Connect. C.G. is supported by Swiss National Science Foundation (grant no. 10030_152638), the Rheumasearch Foundation, and the Institute of Arthritis Research.
Disclosure of potential conflict of interest: C. Girard's institution has received a grant from AB2Bio. J. Kelsen's institution has received grant K23 from the National Institutes of Health (NIH). A. Sleight and E. Schiffrin are employed by AB2 Bio, Ltd. C. Gabay has received a grant and consulting fees from AB2 Bio for this work and consultancy fees from Roche, BMS, Merck, Pfizer, Novartis, Celgene, and Sanofi for other work. R. Goldbach-Mansky's institution has received grants from SOBI, Lilly, Regeneron, and Novartis. E. M. Behrens' institution has received a grant from the NIH, Sean Fischel Connect, and Nancy Taylor Foundation; he has received a consulting fee from AB2Bio and a grant from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
Scott W. Canna, MD, is currently affiliated with Children's Hospital of Pittsburgh, Pittsburgh, Pa.
- ‡
Adriana de Jesus, MD, PhD, and Raphaela Goldbach-Mansky, MD, MHS, are currently affiliated with IRP National Institute of Allergy and Infectious Diseases, Bethesda, Md.